- FoI Number
- 2024-152
- Subject
- Oncology Breast Cancer
- Date Received
- 03/06/2024
- Request and Response
-
- How many patients have been treated for breast cancer (any stage) in the past 3 months with the following systemic anti-cancer therapies:
Therapy
Number of Patients treated
Abemaciclib + Aromatase Inhibitor (e.g. anastrazole, exemestane, letrozole)
0
Abemaciclib + Fulvestrant
0
Alpelisib + Fulvestrant
0
Anthracycline (e.g. doxorubicin or epirubicin) + Cyclophosphamide
<5
Aromatase Inhibitor as a single agent
<5
Atezolizumab
0
Capecitabine as a single agent
<5
Carboplatin + Paclitaxel
0
Eribulin as a single agent or in combination Everolimus + Exemestane
0
Fulvestrant as a single agent
0
Palbociclib + Aromatase Inhibitor (e.g. anastrazole, exemestane, letrozole)
0
Palbociclib + Fulvestrant
<5
Parp Inhibitors (Olaparib/Talazoparib)
<5
Pembrolizumab
0
Ribociclib + Aromatase Inhibitor (e.g. anastrazole, exemestane, letrozole)
0
Ribociclib + Fulvestrant
0
Sacituzumab Govitecan
0
Taxane (e.g. docetaxel, paclitaxel, nab-paclitaxel) as a single agent
0
Transtuzumab deruxtecan
0
Trastuzumab as a single agent or in combination
0
Trastuzumab emtansine
<5
Any other active systemic anti-cancer therapy
0
